Catherine Lee, MD
Hematology & Oncology · Seattle, WANPI 1871734038
Payments from drug & device makers
Across 243 payments — averaging $3907.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$325K
- Incyte Corporation$290K
- Astellas Pharma Global Development$109K
- Sanofi US Services Inc.$75K
- Sanofi-aventis U.S. LLC$71K
- Bristol Myers Squibb$24K
- plus $55K from 11 others
What the payments were for
- Consulting fees$131,50266%
- Speaking & faculty fees$47,92724%
- Travel & lodging$15,9448%
- Food & beverage$3,9662%
- Education$1350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 68 | $325,382 |
| Incyte Corporation | 69 | $289,608 |
| Astellas Pharma Global Development | 8 | $108,895 |
| Sanofi US Services Inc. | 10 | $75,409 |
| Sanofi-aventis U.S. LLC | 34 | $71,122 |
| Bristol Myers Squibb | 3 | $23,873 |
| Jazz Pharmaceuticals Inc. | 27 | $17,915 |
| Sanofi | 6 | $13,684 |
| National Marrow Donor Program | 7 | $13,492 |
| Fresenius Kabi USA, LLC | 1 | $5,600 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,076 |
| Kadmon Pharmaceuticals LLC | 3 | $2,051 |
| Seagen Inc. | 1 | $95 |
| Medexus Pharma, Inc. | 1 | $92 |
| United Therapeutics Corporation | 2 | $68 |
| Novartis | 1 | $60 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$949,436 in reported general payments places this provider in the 85th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Seattle
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Chaitra UjjaniSeattle$10.6M
- Lawrence FongSeattle$9.7M
- Cameron TurtleSeattle$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.